WallStSmart

EastGroup Properties Inc (EGP)vsLineage, Inc. Common Stock (LINE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 644% more annual revenue ($5.36B vs $719.57M). EGP leads profitability with a 35.8% profit margin vs -1.9%. EGP earns a higher WallStSmart Score of 59/100 (C).

EGP

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 7.5Value: 4.7Quality: 5.0

LINE

Avoid

34

out of 100

Grade: F

Growth: 3.3Profit: 5.0Value: 5.0Quality: 3.8
Piotroski: 5/9Altman Z: 0.81
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EGPSignificantly Overvalued (-87.4%)

Margin of Safety

-87.4%

Fair Value

$101.32

Current Price

$183.09

$81.77 premium

UndervaluedFair: $101.32Overvalued

Intrinsic value data unavailable for LINE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EGP3 strengths · Avg: 9.3/10
Profit MarginProfitability
35.8%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
40.5%10/10

Strong operational efficiency at 40.5%

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Areas to Watch

EGP3 concerns · Avg: 3.0/10
P/E RatioValuation
39.1x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

PEG RatioValuation
8.422/10

Expensive relative to growth rate

LINE4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-119.0%2/10

ROE of -119.0% — below average capital efficiency

Revenue GrowthGrowth
-20.0%2/10

Revenue declined 20.0%

Altman Z-ScoreHealth
0.812/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : EGP

The strongest argument for EGP centers on Profit Margin, Operating Margin, Price/Book. Profitability is solid with margins at 35.8% and operating margin at 40.5%. Revenue growth of 14.3% demonstrates continued momentum.

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bear Case : EGP

The primary concerns for EGP are P/E Ratio, Return on Equity, PEG Ratio.

Bear Case : LINE

The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

EGP profiles as a mature stock while LINE is a turnaround play — different risk/reward profiles.

EGP is growing revenue faster at 14.3% — sustainability is the question.

LINE generates stronger free cash flow (78M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EGP scores higher overall (59/100 vs 34/100), backed by strong 35.8% margins and 14.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

EastGroup Properties Inc

REAL ESTATE · REIT - INDUSTRIAL · USA

EastGroup Properties, Inc. (NYSE: EGP), an S&P MidCap 400 company, is a self-managed capital real estate investment trust focused on the development, acquisition and operation of industrial properties in Sunbelt's major markets in the United States. with an emphasis on the states of Florida, Texas, Arizona, California and North Carolina.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company at the forefront of regenerative medicine, specializing in the development of advanced cell therapy solutions aimed at treating severe diseases such as eye disorders, spinal cord injuries, and cancer. Leveraging proprietary technologies and a strong commitment to strategic partnerships, the company is dedicated to revolutionizing patient care with its novel therapeutic approaches. As Lineage continues to enhance its diverse product pipeline and accelerate clinical research initiatives, it represents a compelling opportunity for institutional investors looking to support transformative advancements in healthcare.

Visit Website →

Want to dig deeper into these stocks?